EGNN-Designed Immunomodulatory Compounds for PD-1/PD-L1 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using PD-1/PD-L1 inhibitors, such as monoclonal antibodies, are limited by their slow action and difficulty in penetrating cell membranes, necessitating the development of small-molecule inhibitors with enhanced immunomodulatory activities.
Innovation Solution
A machine learning framework is employed to design and test novel PD-1/PD-L1 inhibitors using a combination of local and global features from molecular graphs, predicting compounds with high potency through an EGNN model, and validating them with docking simulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as PD-1/PD-L1 inhibitors, then immunomodulatory activity is achieved, but the treatment acts slowly and has difficulty penetrating cell membranes
Solution Approach 1:
The invention changes the molecular parameters from large monoclonal antibodies to small molecule compounds, fundamentally altering the physical and chemical properties to achieve faster action and improved membrane penetration while maintaining immunomodulatory activity through PD-1/PD-L1 inhibition
Solution Approach 2:
The invention extracts the essential functional property (PD-1/PD-L1 binding capability) from the complex monoclonal antibody structure and implements it through simplified small molecule compounds, removing the bulk of the antibody structure that causes slow action and penetration issues
2Reliability
If monoclonal antibodies are used as PD-1/PD-L1 inhibitors, then immunomodulatory activity is achieved, but penetration through cell membranes is difficult
Solution Approach 1:
The invention fundamentally changes the size parameter by transitioning from large monoclonal antibodies (150 kDa) to small molecule compounds (<1 kDa), enabling passive diffusion through cell membranes via hydrophobic pathways while preserving the ability to inhibit PD-1/PD-L1 interaction
Solution Approach 2:
The invention extracts only the essential binding functionality from the large antibody molecule and implements it through compact small molecule structures, eliminating the size-related barriers to membrane penetration
Data Source
AI summary
The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.